Presented in part at the 86th Annual Meeting, Canadian Dermatology Association, 22–26 June 2011, Edmonton, Alberta, Canada.
Pharmacology and therapeutics
Efficacy of topical calcineurin inhibitors in vitiligo
Version of Record online: 20 JAN 2013
© 2013 The International Society of Dermatology
International Journal of Dermatology
Volume 52, Issue 4, pages 491–496, April 2013
How to Cite
Wong, R. and Lin, A. N. (2013), Efficacy of topical calcineurin inhibitors in vitiligo. International Journal of Dermatology, 52: 491–496. doi: 10.1111/j.1365-4632.2012.05697.x
Conflict of interest: Dr Lin has been a paid speaker for Astellas Pharma Canada Inc.
American trade names: tacrolimus: PROTOPIC; pimecrolimus: ELIDEL.
- Issue online: 15 MAR 2013
- Version of Record online: 20 JAN 2013
- Manuscript Accepted: 22 APR 2012
- Manuscript Revised: 25 MAR 2012
- Manuscript Received: 21 JAN 2012
Options for accessing this content:
- If you are a society or association member and require assistance with obtaining online access instructions please contact our Journal Customer Services team.
- If your institution does not currently subscribe to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
- New Users: Please register, then proceed to purchase the article.
Login via OpenAthens
Search for your institution's name below to login via Shibboleth.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.